The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults
BRIO
2 other identifiers
interventional
300
1 country
2
Brief Summary
To critically examine biological, clinical, and behavioral modulators of progressive resistance training-associated exercise response heterogeneity in physical function and whole-body metabolism in older adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 2025
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 16, 2025
CompletedFirst Posted
Study publicly available on registry
April 23, 2025
CompletedStudy Start
First participant enrolled
August 11, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2030
September 16, 2025
August 1, 2025
4.1 years
January 16, 2025
September 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Precisely define the variability in changes in physical function
Measured by the Short Physical Performance Battery (SPPB), a 0-12 categorical scale of walking speed, standing balance, and repeated sit-to-stand time, with higher scores reflecting better physical function.
baseline, 6 months
Precisely define the variability in changes in blood glucose concentrations in response to a meal tolerance test
Blood glucose concentrations (millimoles/liter) will be measured in response to a physiologically relevant meal challenge. Lower values are indicative of better metabolic health.
baseline, 6 months
Secondary Outcomes (7)
Precisely define the variability in changes in skeletal muscle size.
baseline, 6 months
Precisely define the variability in changes in skeletal muscle strength.
baseline, 6 months
Precisely define the variability in changes in six-minute walk distance.
baseline, 6 months
Precisely define the variability in insulin secretion in response to a mixed meal tolerance test.
baseline, 6 months
Precisely define the variability in changes in the percentage of glycated hemoglobin in the blood.
baseline, 6 months
- +2 more secondary outcomes
Study Arms (2)
Progressive Resistance Training
OTHERparticipants will attend exercise session 3 times per week.
Health Education
OTHERparticipants will attend health educations classed 1 time per week.
Interventions
Eligibility Criteria
You may qualify if:
- aged greater than or equal to 65 years
- sedentary (Community Healthy Activities Model Program for Seniors physical activity questionnaire to identify and exclude persons engaged in regular (125 min/week or more) moderate intensity physical activity
- at risk for mobility disability score of less than or equal to 10 (but greater than 3) on the SPPB
- willing to be randomized into HE or PRT
- willing to be transported or transport themselves to the clinical sites for the intervention and assessments
You may not qualify if:
- unwillingness to provide informed consent
- participation in lifestyle or pharmacologic intervention trial or structured program of exercise training in the past 6 months
- an SPPB score of less than or equal to 3
- osteoarthritis or condition with joint pain limiting daily life activities
- significant weight loss or gain (7.5% of body weight) in past six months
- current anti-coagulant or anti-platelet therapy (Coumadin, Eliquis, Pradaxa, Xarelto, heparin, Lovenox, Plavix)
- clinically significant abnormality in any of the screening laboratory values, including those identified as outside of the "normal limits', that are deemed to be of concern for participation in the study by the study physician
- acute or terminal illness
- Mini Mental State Exam (MMSE) \<23
- myocardial infarction in the previous 6 months or other symptomatic coronary artery disease
- New York Heart Association Class III or IV congestive heart failure
- serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (\>3 mm) on ECG
- chronic obstructive pulmonary disease requiring oxygen therapy
- upper or lower extremity fracture in the previous 6 months
- uncontrolled hypertension (150/90 mm Hg)
- +11 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University
Boston, Massachusetts, 02111, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nathan LeBrasseur, Ph.D, MS
Mayo Clinic
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Data analysis team
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 16, 2025
First Posted
April 23, 2025
Study Start
August 11, 2025
Primary Completion (Estimated)
August 31, 2029
Study Completion (Estimated)
August 31, 2030
Last Updated
September 16, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share